{"Title":"Sienna Biopharmaceuticals","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"40","Founded":"","Address":"","Phone":"(818) 629-2256","Web_address":"http://www.SiennaBio.com","Market_cup":"$298.3mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-27.4 mil (last 12 months)","Symbol":"SNNA","Exchange":"NASDAQ","Shares":"4.3","Price_range":"$15.00 - $15.00","Est_volume":"$65.0 mil","Manager":"J.P. Morgan/ Cowen/ BMO Capital Markets","CO_managers":"-","Exp_to_trade":"7/27/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Our objective is to develop our multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology patients. We are advancing multiple product candidates derived from our Topical by Design™ platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions."}